merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Because Eli Lilly's cheaper, FDA-approved Zepbound vials offer a safer alternative, undermining the market for less-regulated compounded drugs.</answer>
<question_number>2</question_number>
<answer>By providing telehealth prescriptions and direct delivery of Zepbound vials through LillyDirect, challenging telehealth companies' models.</answer>
<question_number>3</question_number>
<answer>The safety risks due to less oversight and regulatory control of compounded weight-loss drugs.</answer>
<question_number>4</question_number>
<answer>Because offering lower-priced vials can regain customers from compounded drugs, increasing market share despite cannibalizing pen sales.</answer>
<question_number>5</question_number>
<answer>The FDA's shortage list allows compounding pharmacies to produce tirzepatide; removing it aids Lilly's legal challenges against them.</answer>
<question_number>6</question_number>
<answer>By selling directly to consumers at lower prices, eliminating intermediaries, reflecting a trend toward direct-to-consumer sales.</answer>
<question_number>7</question_number>
<answer>Risk of older Medicare patients using the drugs despite coverage denial, leading to health concerns like muscle loss.</answer>
<question_number>8</question_number>
<answer>It highlights safety concerns with compounded drugs, potentially shifting patients to prefer Eli Lilly's FDA-approved vials.</answer>
<question_number>9</question_number>
<answer>Being on the FDA's "in shortage" list allows compounding pharmacies to produce tirzepatide.</answer>
<question_number>10</question_number>
<answer>By lowering prices to undercut compounded drugs, indirectly regaining market share from compounding pharmacies.</answer>